Target intelligence / Profile preview

Mitogen-activated protein kinase kinase kinase 9 (MAP3K9)

Target
MAP3K9
Molecular classification
Enzyme, Kinase, Serine/threonine kinase
01

Overview

Mitogen-activated protein kinase kinase kinase 9 (MAP3K9), also known as Mixed lineage kinase 1 (MLK1), is a serine/threonine-protein kinase belonging to the mixed-lineage kinase (MLK) family of the MAP3K superfamily. It acts as an essential upstream regulator of the c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) signaling pathways by phosphorylating and activating MAP2K4/MKK4 and MAP2K7/MKK7. MAP3K9 plays a critical role in regulating cellular responses to environmental stress, cell death, apoptosis, neuronal development, and cell proliferation. Dysregulation, overexpression, or mutations of MAP3K9 have been implicated in various cancers (such as prostate, pancreatic, and melanoma) and neurodegenerative disorders (such as Parkinson's and Alzheimer's diseases). Small molecule inhibitors targeting MAP3K9, such as CEP-1347 and URMC-099, have been investigated for their neuroprotective, anti-inflammatory, and anti-tumor properties. Although CEP-1347 showed promise in preclinical models, it failed to demonstrate clinical efficacy in Phase II/III trials for Parkinson's disease, highlighting the therapeutic challenges of targeting this pathway.

Other names
Mixed lineage kinase 1MLK1PRKE1MEKK9
02

Mechanism of action

ATP-competitive kinase inhibition

03

Biological functions

Signal transductionApoptosisCell deathCell proliferationStress responseNeuronal development
04

Disease associations

CancerNeurodegenerative diseaseInflammationAsthma
05

Safety considerations

Off-target kinase inhibitionSystemic toxicity from JNK/p38 pathway suppressionEmbryo-fetal toxicityLack of clinical efficacy in neurodegenerative diseases
06

Interacting drugs

4 more in the full profile.

07

Biomarkers

Phosphorylated JNK (pJNK)Phosphorylated c-Jun (p-c-Jun)MAP3K9 expression levelsmiR-328-3p expression

Beyond the preview

Go deeper on Mitogen-activated protein kinase kinase kinase 9 (MAP3K9).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitogen-activated protein kinase kinase kinase 9 (MAP3K9).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call